Key Points
- David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics on April 15 at an average price of $27.66 for $175,585.68, reducing his stake by 8.34% to 69,792 shares valued at about $1.93 million; the trade was disclosed to the SEC and executed under a pre-arranged Rule 10b5-1 plan.
- This April 15 sale is part of a string of recent disposals by Rodman (Jan–Apr), totaling **68,561 shares** and roughly **$1.87 million** in proceeds across multiple transactions.
- For context, MLYS shares recently opened near $30.42, the company has a market cap of about $2.51 billion, and analysts hold a consensus **"Moderate Buy"** with an average price target of $49.14.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $27.66, for a total transaction of $175,585.68. Following the sale, the insider owned 69,792 shares in the company, valued at $1,930,446.72. This represents a 8.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Malcom Rodman also recently made the following trade(s):
- On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.54, for a total transaction of $373,099.32.
- On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.38, for a total transaction of $59,414.60.
- On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total transaction of $173,744.76.
- On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.26, for a total transaction of $369,163.08.
- On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total transaction of $58,269.64.
- On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total transaction of $11,505.03.
- On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.99, for a total transaction of $184,057.51.
- On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.44, for a total transaction of $385,669.20.
- On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.21, for a total transaction of $65,585.91.
- On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.10, for a total transaction of $13,353.60.
Mineralys Therapeutics Price Performance
Shares of NASDAQ:MLYS opened at $30.42 on Thursday. The company's fifty day moving average price is $27.26 and its 200 day moving average price is $34.36. Mineralys Therapeutics, Inc. has a 12 month low of $12.59 and a 12 month high of $47.65. The firm has a market capitalization of $2.51 billion, a P/E ratio of -12.84 and a beta of 0.69.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, sell-side analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the stock. HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a research report on Tuesday, March 10th. Wall Street Zen raised shares of Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, March 15th. Stifel Nicolaus raised their price objective on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a research report on Friday, December 19th. Bank of America raised their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a "buy" rating in a research report on Friday, March 13th. Finally, Jefferies Financial Group reissued a "hold" rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Friday, March 13th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $49.14.
Get Our Latest Research Report on Mineralys Therapeutics
Institutional Trading of Mineralys Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in MLYS. Navalign LLC purchased a new stake in shares of Mineralys Therapeutics in the fourth quarter valued at about $33,000. Smartleaf Asset Management LLC boosted its holdings in shares of Mineralys Therapeutics by 198.2% in the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company's stock valued at $40,000 after acquiring an additional 676 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company's stock valued at $56,000 after acquiring an additional 1,107 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Mineralys Therapeutics by 1,845.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company's stock valued at $76,000 after acquiring an additional 1,993 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Mineralys Therapeutics by 14,091.3% in the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company's stock valued at $124,000 after acquiring an additional 3,241 shares in the last quarter. Hedge funds and other institutional investors own 84.46% of the company's stock.
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
